LynxDx
LynxDx offers a prostate cancer risk assessment tool, MyProstateScore 2.0, which utilizes a urine test and analyzes 18 gene transcripts to predict clinically significant prostate cancer.
Prostate Cancer Risk Assessment Tool
LynxDx offers a prostate cancer risk assessment tool known as MyProstateScore 2.0. This tool leverages a urine test to predict the presence of clinically significant prostate cancer. By analyzing 18 unique gene transcripts, it aims to optimize diagnostic accuracy and provide clinical flexibility. This allows for a personalized approach to prostate cancer screening, enhancing the predictive power of the results.
Individualized Patient Reports
LynxDx provides individualized reports tailored to unique patient and clinical contexts. The detailed reports are designed to support healthcare providers in making informed decisions based on each patient's specific risk profile. This level of personalization aids in delivering precise and actionable insights for the effective management of prostate cancer risk.
Certifications and Licensures
LynxDx holds Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologist (CAP) certifications. These certifications affirm the company's commitment to maintaining high standards of laboratory practice. Furthermore, LynxDx is licensed to operate in several states including California, Maryland, Rhode Island, and Pennsylvania, ensuring wide accessibility to its diagnostic services.
Research and Validation
LynxDx has participated in peer-reviewed research validating the efficacy of MyProstateScore 2.0. Findings published in JAMA Oncology support the tool's ability to predict the presence of clinically significant prostate cancer accurately. This research underscores the company's dedication to evidence-based medical practices and its continuous effort to improve cancer diagnostics.
Resources for Providers and Patients
LynxDx has developed a comprehensive array of resources to support both providers and patients in the assessment of prostate cancer risk. These resources include educational materials, guidelines, and tools that facilitate better understanding and usage of MyProstateScore 2.0. By equipping stakeholders with the necessary information, LynxDx aims to enhance the overall effectiveness of prostate cancer screening and management.